Vincerx Historical Financial Ratios

VINC Stock

USD 0.56 0.09 13.85%

Vincerx Pharma is promptly reporting on over 92 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0, PTB Ratio of 42.32 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Vincerx Pharma financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vincerx Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Vincerx Stock refer to our How to Trade Vincerx Stock guide.

About Vincerx Financial Ratios Analysis

Vincerx PharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Vincerx Pharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Vincerx financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Vincerx Pharma history.

Vincerx Pharma Financial Ratios Chart

At present, Vincerx Pharma's PB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Days Payables Outstanding is expected to grow to 936.55, whereas Book Value Per Share is forecasted to decline to 0.58.

Payables Turnover Cash Per Share Days Payables Outstanding Income Quality

Add Fundamental

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Income Quality

An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.

Most ratios from Vincerx Pharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Vincerx Pharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vincerx Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Vincerx Stock refer to our How to Trade Vincerx Stock guide.At present, Vincerx Pharma's PB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Days Payables Outstanding is expected to grow to 936.55, whereas Book Value Per Share is forecasted to decline to 0.58.

Vincerx Pharma fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Net Debt To E B I T D A
Ptb Ratio		0.67	-0.75	-0.87	-0.46	1.0	-0.88	-0.72	0.46	-0.89	0.47	-1.0	0.65	1.0	0.47	0.45	1.0	0.9	0.27	-0.83	1.0	1.0	-0.69	1.0	-0.74	1.0
Book Value Per Share	0.67		-0.14	-0.44	0.06	0.67	-0.48	0.0	-0.06	-0.34	-0.06	-0.69	1.0	0.66	-0.06	-0.05	0.66	0.86	-0.05	-0.17	0.66	0.67	0.04	0.66	-0.11	0.69
Free Cash Flow Yield	-0.75	-0.14		0.92	0.54	-0.75	0.89	0.82	-0.53	0.97	-0.54	0.75	-0.12	-0.77	-0.54	-0.52	-0.77	-0.6	-0.56	0.84	-0.77	-0.76	0.82	-0.77	1.0	-0.73
Operating Cash Flow Per Share	-0.87	-0.44	0.92		0.53	-0.87	1.0	0.78	-0.51	0.96	-0.52	0.88	-0.42	-0.89	-0.52	-0.5	-0.89	-0.83	-0.61	0.84	-0.89	-0.88	0.77	-0.89	0.91	-0.86
Capex To Depreciation	-0.46	0.06	0.54	0.53		-0.46	0.51	0.75	-0.77	0.58	-0.8	0.45	0.07	-0.47	-0.8	-0.73	-0.47	-0.22	-0.01	0.72	-0.47	-0.46	0.75	-0.47	0.56	-0.45
Pb Ratio	1.0	0.67	-0.75	-0.87	-0.46		-0.88	-0.72	0.46	-0.89	0.47	-1.0	0.65	1.0	0.47	0.45	1.0	0.9	0.27	-0.83	1.0	1.0	-0.69	1.0	-0.74	1.0
Free Cash Flow Per Share	-0.88	-0.48	0.89	1.0	0.51	-0.88		0.76	-0.49	0.94	-0.5	0.88	-0.47	-0.9	-0.5	-0.48	-0.9	-0.86	-0.61	0.82	-0.89	-0.88	0.74	-0.89	0.88	-0.86
Roic	-0.72	0.0	0.82	0.78	0.75	-0.72	0.76		-0.76	0.85	-0.77	0.71	0.02	-0.74	-0.77	-0.75	-0.74	-0.44	-0.47	0.98	-0.74	-0.72	1.0	-0.74	0.83	-0.7
Inventory Turnover	0.46	-0.06	-0.53	-0.51	-0.77	0.46	-0.49	-0.76		-0.56	1.0	-0.44	-0.07	0.47	1.0	1.0	0.47	0.21	0.24	-0.73	0.47	0.46	-0.76	0.47	-0.54	0.45
Net Income Per Share	-0.89	-0.34	0.97	0.96	0.58	-0.89	0.94	0.85	-0.56		-0.57	0.89	-0.32	-0.9	-0.57	-0.55	-0.9	-0.74	-0.47	0.9	-0.9	-0.9	0.84	-0.9	0.96	-0.88
Days Of Inventory On Hand	0.47	-0.06	-0.54	-0.52	-0.8	0.47	-0.5	-0.77	1.0	-0.57		-0.45	-0.07	0.48	1.0	0.99	0.48	0.22	0.23	-0.74	0.48	0.47	-0.78	0.48	-0.55	0.45
Payables Turnover	-1.0	-0.69	0.75	0.88	0.45	-1.0	0.88	0.71	-0.44	0.89	-0.45		-0.67	-1.0	-0.45	-0.43	-1.0	-0.91	-0.28	0.82	-1.0	-1.0	0.68	-1.0	0.74	-1.0
Cash Per Share	0.65	1.0	-0.12	-0.42	0.07	0.65	-0.47	0.02	-0.07	-0.32	-0.07	-0.67		0.64	-0.07	-0.07	0.64	0.85	-0.04	-0.15	0.64	0.65	0.07	0.64	-0.09	0.67
Pocfratio	1.0	0.66	-0.77	-0.89	-0.47	1.0	-0.9	-0.74	0.47	-0.9	0.48	-1.0	0.64		0.48	0.46	1.0	0.9	0.31	-0.84	1.0	1.0	-0.71	1.0	-0.76	1.0
Interest Coverage	0.47	-0.06	-0.54	-0.52	-0.8	0.47	-0.5	-0.77	1.0	-0.57	1.0	-0.45	-0.07	0.48		0.99	0.48	0.22	0.23	-0.74	0.48	0.47	-0.78	0.48	-0.55	0.45
Capex To Operating Cash Flow	0.45	-0.05	-0.52	-0.5	-0.73	0.45	-0.48	-0.75	1.0	-0.55	0.99	-0.43	-0.07	0.46	0.99		0.46	0.21	0.25	-0.72	0.46	0.45	-0.75	0.46	-0.53	0.44
Pfcf Ratio	1.0	0.66	-0.77	-0.89	-0.47	1.0	-0.9	-0.74	0.47	-0.9	0.48	-1.0	0.64	1.0	0.48	0.46		0.9	0.31	-0.84	1.0	1.0	-0.71	1.0	-0.76	1.0
Days Payables Outstanding	0.9	0.86	-0.6	-0.83	-0.22	0.9	-0.86	-0.44	0.21	-0.74	0.22	-0.91	0.85	0.9	0.22	0.21	0.9		0.35	-0.57	0.9	0.9	-0.4	0.9	-0.57	0.9
Income Quality	0.27	-0.05	-0.56	-0.61	-0.01	0.27	-0.61	-0.47	0.24	-0.47	0.23	-0.28	-0.04	0.31	0.23	0.25	0.31	0.35		-0.43	0.31	0.28	-0.47	0.31	-0.54	0.24
Roe	-0.83	-0.17	0.84	0.84	0.72	-0.83	0.82	0.98	-0.73	0.9	-0.74	0.82	-0.15	-0.84	-0.74	-0.72	-0.84	-0.57	-0.43		-0.84	-0.83	0.98	-0.84	0.85	-0.82
Ev To Operating Cash Flow	1.0	0.66	-0.77	-0.89	-0.47	1.0	-0.89	-0.74	0.47	-0.9	0.48	-1.0	0.64	1.0	0.48	0.46	1.0	0.9	0.31	-0.84		1.0	-0.71	1.0	-0.76	1.0
Pe Ratio	1.0	0.67	-0.76	-0.88	-0.46	1.0	-0.88	-0.72	0.46	-0.9	0.47	-1.0	0.65	1.0	0.47	0.45	1.0	0.9	0.28	-0.83	1.0		-0.7	1.0	-0.75	1.0
Return On Tangible Assets	-0.69	0.04	0.82	0.77	0.75	-0.69	0.74	1.0	-0.76	0.84	-0.78	0.68	0.07	-0.71	-0.78	-0.75	-0.71	-0.4	-0.47	0.98	-0.71	-0.7		-0.71	0.84	-0.67
Ev To Free Cash Flow	1.0	0.66	-0.77	-0.89	-0.47	1.0	-0.89	-0.74	0.47	-0.9	0.48	-1.0	0.64	1.0	0.48	0.46	1.0	0.9	0.31	-0.84	1.0	1.0	-0.71		-0.76	1.0
Earnings Yield	-0.74	-0.11	1.0	0.91	0.56	-0.74	0.88	0.83	-0.54	0.96	-0.55	0.74	-0.09	-0.76	-0.55	-0.53	-0.76	-0.57	-0.54	0.85	-0.76	-0.75	0.84	-0.76		-0.72
Net Debt To E B I T D A	1.0	0.69	-0.73	-0.86	-0.45	1.0	-0.86	-0.7	0.45	-0.88	0.45	-1.0	0.67	1.0	0.45	0.44	1.0	0.9	0.24	-0.82	1.0	1.0	-0.67	1.0	-0.72

Click cells to compare fundamentals

Vincerx Pharma Account Relationship Matchups

Vincerx Pharma fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	101.38	34.89	9.0	44.78	40.31	42.32
Book Value Per Share	4.13	5.84	2.27	0.53	0.61	0.58
Free Cash Flow Yield	(3.9E-4)	(0.011)	(0.14)	(0.0805)	(0.0926)	(0.0972)
Operating Cash Flow Per Share	(0.16)	(1.94)	(2.83)	(1.9)	(2.18)	(2.29)
Pb Ratio	101.38	34.89	9.0	44.78	40.31	42.32
Free Cash Flow Per Share	(0.16)	(2.25)	(2.83)	(1.9)	(2.18)	(2.29)
Roic	(0.19)	(0.24)	(1.23)	(3.09)	(3.56)	(3.38)
Net Income Per Share	(0.77)	(0.91)	(2.72)	(1.89)	(2.17)	(2.28)
Payables Turnover	0.35	0.17	0.23	0.37	0.42	0.4
Cash Per Share	4.42	6.49	2.49	0.6	0.69	0.66
Pocfratio	(2.6K)	(104.8)	(7.2)	(12.42)	(11.18)	(11.74)
Pfcf Ratio	(2.6K)	(90.54)	(7.2)	(12.42)	(11.18)	(11.74)
Days Payables Outstanding	1.0K	2.2K	1.6K	996.07	896.46	936.55
Roe	(0.19)	(0.16)	(1.2)	(3.58)	(4.12)	(3.91)
Ev To Operating Cash Flow	(2.5K)	(101.59)	(7.06)	(12.17)	(10.95)	(11.5)
Pe Ratio	(545.04)	(224.27)	(7.51)	(12.51)	(11.26)	(11.83)
Ev To Free Cash Flow	(2.5K)	(87.77)	(7.06)	(12.17)	(10.95)	(11.5)
Earnings Yield	(0.001835)	(0.004459)	(0.13)	(0.0799)	(0.0919)	(0.0965)
Net Debt To E B I T D A	5.77	1.71	0.12	0.24	0.22	0.23
Current Ratio	11.46	8.04	6.11	2.63	3.02	2.87
Tangible Book Value Per Share	4.13	5.84	2.27	0.53	0.61	0.58
Shareholders Equity Per Share	4.13	5.84	2.27	0.53	0.61	0.58
Graham Net Net	4.02	5.48	1.96	0.27	0.31	0.3
Enterprise Value Over E B I T D A	(540.09)	(54.16)	(6.13)	(11.55)	(13.29)	(12.62)
Price Earnings Ratio	(545.04)	(224.27)	(7.51)	(12.51)	(11.26)	(11.83)
Price Book Value Ratio	101.38	34.89	9.0	44.78	40.31	42.32
Days Of Payables Outstanding	1.0K	2.2K	1.6K	996.07	896.46	936.55
Price To Operating Cash Flows Ratio	(2.6K)	(104.8)	(7.2)	(12.42)	(11.18)	(11.74)
Price To Free Cash Flows Ratio	(2.6K)	(90.54)	(7.2)	(12.42)	(11.18)	(11.74)
Company Equity Multiplier	1.1	1.17	1.24	1.62	1.46	0.82
Return On Capital Employed	(0.19)	(0.6)	(1.47)	(3.38)	(3.89)	(3.69)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Vincerx Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vincerx Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vincerx Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vincerx Pharma Stock:

How To Invest In Vincerx

Details

Is Vincerx Stock a good investment?

Details

What is Vincerx Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Vincerx Stock refer to our How to Trade Vincerx Stock guide.

You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vincerx Pharma. If investors know Vincerx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vincerx Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.14)

Return On Assets

(0.66)

Return On Equity

(1.42)

The market value of Vincerx Pharma is measured differently than its book value, which is the value of Vincerx that is recorded on the company's balance sheet. Investors also form their own opinion of Vincerx Pharma's value that differs from its market value or its book value, called intrinsic value, which is Vincerx Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vincerx Pharma's market value can be influenced by many factors that don't directly affect Vincerx Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Vincerx Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vincerx Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vincerx Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Vincerx Historical Financial Ratios

About Vincerx Financial Ratios Analysis

Vincerx Pharma Financial Ratios Chart

Payables Turnover

Income Quality

Vincerx Pharma fundamentals Correlations

Vincerx Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vincerx Pharma fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Pocfratio	+ 1.0	Ptb Ratio
Pfcf Ratio	+ 1.0	Ptb Ratio
Ev To Operating Cash Flow	+ 1.0	Ptb Ratio
Pe Ratio	+ 1.0	Ptb Ratio
Ev To Free Cash Flow	+ 1.0	Ptb Ratio

Net Debt To E B I T D A	- 1.0	Payables Turnover
Ev To Free Cash Flow	- 1.0	Payables Turnover
Pe Ratio	- 1.0	Payables Turnover
Ev To Operating Cash Flow	- 1.0	Payables Turnover
Pfcf Ratio	- 1.0	Payables Turnover
Pocfratio	- 1.0	Payables Turnover